Коррекция нарушений липидного обмена у больных сахарным диабетом типа 2

1. Nathan DM, Meigs J, Singer DE. The Epidemiology of Cardiovascular Disease in Type 2 Diabetes Mellitus: How Sweet It Is ... or Is It? Lancet 1997; 350 (Suppl. 1): S4–S8.
2. Pyorala K, Laakso M, Uusitupa M. Diabetes and Atherosclerosis: an Epidemiologic View. Diabetes Metab Rev 1987; 3: 463–524.
3. Betteridge DJ. Epidemiology of the Cardiac Complications of Type 2 Diabetes Mellitus. Medicographia 2001; 23: 95–9.
4. Gerstein HC. Epidemiology of Heart Disease in Diabetes. Stanley WC, Ryden L. (ed). The Diabetic Coronary Patient. London: Science Press, 1999: 3–12.
5. Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and Cardiovascular Disease. A Statement for Healthcare Professionals from the American Heart Association. Circulation 1999; 100: 1134–46.
6. Wilson PWF, Anderson KM, Kannel WB. Epidemiology of Diabetes Mellitus in the Eldery: the Framingham Offspring Study. Am J Med 1986; 80 (Suppl. 5A): 3–9.
7. Wingard DL, Barrett-Connors E, Criqui MH, Suarez L. Clustering of Heart Disease Risk Factors in Diabetic Compared to Nondiabetic Adults. Am J Epidemiol 1983; 117: 19–26
8. Laakso M. Epidemiology of Diabetic Dyslipidemia. Diabetes Rev 1995; 3: 408–22.
9. Steiner G. Risk Factors for Macrovascular Disease in Type 2 Diabetes. Classic Lipid Abnormalities. Diabetes Care 1999; 22 (Suppl. 3): C6–C9.
10. Ronnemaa T, Laakso M, Kallio V et al. Serum Lipids, Lipoproteins, and Apolipoproteins and the Excessive Occurrence of Coronary Heart Disease in Non-Insulin-Dependent Diabetic Patients. Am J Epidemiol 1989; 130: 632–45.
11. Syvanne M, Taskinen M-R. Lipids and Lipoproteins as Coronary Risk Factors in Non-Insulin-Dependent Diabetes Mellitus. Lancet 1997; 350 (Suppl. I): 20–3.
12. Feingold KR, Grunfeld C, Pang M et al. LDL Subclass Phenotypes and Triglyceride Metabolism in Nnon-Insulin-Dependent Diabetes. Arterioscler Thromb 1992; 12: 1496–502.
13. Chapman MJ, Guerin M, Bruckert E. Atherogenic, Dense Low-Density Lipoproteins. Pathophysiologyb and New Therapeutic Approaches. Eur Heart J 1998; 19 (Suppl. A): A24–A30.
14. Superko HR. Lipoprotein Subclasses and Atherosclerosis. Frontiers in Bioscience 2001; 6: d355–d365.
15. Lyons TJ. Oxidized Low Density Lipoproteins: a Role in the Pathogenesis of Atherosclerosis in Diabetes? Diabetic Med 1991; 8: 411–9.
16. Turner RC, Millns H, Neil HA et al. Risk Factors for Coronary Artery Disease in Non-Insulin-Dependent Diabetes Mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). Br Med J 1998; 316: 823–8.
17. Fontbonne A, Eschwege E, Cambien F et al. Hypertriglyceridaemia as a Risk Factor of Coronary Heart Disease Mortality in Subjects with Impaired Glucose Tolerance or Diabetes. Results from the 11-year Follow-up of the Paris Prospective Study. Diabetologia 1989; 32: 300–4.
18. West KM, Ahuja MM, Bennett PH et al. The Role of Circulating Glucose and Triglyceride Concentrations and Their Interactions With Other “Risk Factors” as Determinants of Arterial Disease in Nine Diabetic Population Samples from the WHO Multinational Study. Diabetes Care 1983; 6: 361–9.
19. Pyorala K, Pedersen TR, Kjekshus J et al. Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A Subgroup Analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614–20.
20. Goldberg RB, Mellies MJ, Sacks FM et al. Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels. Subgroup Analyses in the Cholesterol and Recurrent Events (CARE) Trial. Circulation 1998; 98: 2513–19.
21. Keech A, Colquhoun D, Best J et al. For the LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003; 26: 2713–21.
22. Collins R, Collins R, Armitage J, Parish S. et al. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003; 361: 2005–16.
23. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002; 162: 2597–604.
24. Grundy SM, Cleeman JI, Merz CNB et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227–39.
25. American Diabetes Association. Standards of Medical Care in Diabetes - 2008 (Position Statement). Diabetes Care 2008; 31: S12–S54.
26. Ryden L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88–136.
27. Summury of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97.
28. Colhoun HM, Betteridge DJ, Durrington PN et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–96.

С.Г.Козлов, А.А.Лякишев

Отдел атеросклероза НИИ Кардиологии им. А.Л.Мясникова РКНПК ФГУ Росмедтехнологий, Москва